Closing the gap: prognostic and predictive biomarker validation for personalized care in a Latin American hormone-dependent breast cancer cohort.
Daniela Alves da QuintaDarío RochaJavier RetamalesDiego GiuntaNora ArtagaveytiaCarlos VelazquezAdrian Daneri-NavarroBettina MüllerEliana AbdelhayAlicia I BravoMónica CastroCristina RosalesElsa AlcobaGabriela Acosta HaabFernando CarrizoIrene SorinAlejandro Di SibioMárcia Marques-SilveiraRenata BinatoBenedicta CasertaGonzalo GreifAlicia Del Toro-ArreolaAntonio Quintero-RamosJorge GómezOsvaldo L PodhajcerElmer A Fernándeznull nullAndrea Sabina LleraPublished in: The oncologist (2024)
In summary, we could prove the clinical validity of most transcriptomic-based risk classifiers and their superiority over clinical and immunohistochemical-based methods in the heterogenous, real-world node-negative HR+HER2- MPBCS cohort.